深静脉血栓和肺栓塞的管理与治疗:对美国血液病学会静脉血栓栓塞管理指南的解读

2021-10-20 中国新药与临床杂志

美国血液病学会(ASH)于2020年10月发布的静脉血栓栓塞(VTE)管理指南,针对深静脉血栓(DVT和肺栓塞(PE)的治疗提出了最新推荐意见,笔者结合我国抗凝药物具体情况,对指南中VTE的抗栓综合管

中文标题:

深静脉血栓和肺栓塞的管理与治疗:对美国血液病学会静脉血栓栓塞管理指南的解读

发布机构:

发布日期:

2021-10-20

简要介绍:

美国血液病学会(ASH)于2020年10月发布的静脉血栓栓塞(VTE)管理指南,针对深静脉血栓(DVT和肺栓塞(PE)的治疗提出了最新推荐意见,笔者结合我国抗凝药物具体情况,对指南中VTE的抗栓综合管理进行解读,内容涵盖VTE患者的治疗管理、复发性事件的处理以及VTE合并心血管疾病的治疗建议等。指南推荐新诊断VTE患者的治疗管理分为初始管理、初级治疗和二级预防3个阶段。强烈推荐包括对PE和血流动力学受损的患者先溶栓再抗凝,对使用维生素K拮抗剂作为二级预防的VTE患者的INR范围应控制在2.0~3.0,对复发的不明原因VTE患者应无限期抗凝。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=深静脉血栓和肺栓塞的管理与治疗:对美国血液病学会静脉血栓栓塞管理指南的解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a88ef1c0023319a2, title=深静脉血栓和肺栓塞的管理与治疗:对美国血液病学会静脉血栓栓塞管理指南的解读, enTitle=, guiderFrom=中国新药与临床杂志, authorId=0, author=, summary=美国血液病学会(ASH)于2020年10月发布的静脉血栓栓塞(VTE)管理指南,针对深静脉血栓(DVT和肺栓塞(PE)的治疗提出了最新推荐意见,笔者结合我国抗凝药物具体情况,对指南中VTE的抗栓综合管, cover=https://img.medsci.cn/2022121/1642743446692_5579292.png, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Oct 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">美国血液病学会(ASH)于2020年10月发布的静脉血栓栓塞(VTE)管理指南,针对深静脉血栓(DVT和肺栓塞(PE)的治疗提出了最新推荐意见,笔者结合我国抗凝药物具体情况,对指南中VTE的抗栓综合管理进行解读,内容涵盖VTE患者的治疗管理、复发性事件的处理以及VTE合并心血管疾病的治疗建议等。指南推荐新诊断VTE患者的治疗管理分为初始管理、初级治疗和二级预防3个阶段。强烈推荐包括对PE和血流动力学受损的患者先溶栓再抗凝,对使用维生素K拮抗剂作为二级预防的VTE患者的INR范围应控制在2.0~3.0,对复发的不明原因VTE患者应无限期抗凝。&nbsp;</span></p>, tagList=[TagDto(tagId=302, tagName=深静脉血栓), TagDto(tagId=700, tagName=肺栓塞)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13224, appHits=861, showAppHits=0, pcHits=2126, showPcHits=12362, likes=1, shares=134, comments=23, approvalStatus=1, publishedTime=Fri Jan 21 13:35:19 CST 2022, publishedTimeString=2021-10-20, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Jan 21 13:40:54 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 14:24:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=深静脉血栓和肺栓塞的管理与治疗:对美国血液病学会静脉血栓栓塞管理指南的解读.pdf)])
深静脉血栓和肺栓塞的管理与治疗:对美国血液病学会静脉血栓栓塞管理指南的解读.pdf
下载请点击:
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1249424, encodeId=a7221249424be, content=深静脉血栓是无声杀手,重在预防, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21d85264172, createdName=1480b77bm78暂无昵称, createdTime=Fri Sep 16 22:59:20 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241367, encodeId=0ed4124136e1c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=827a8134685, createdName=ms7000001664629792, createdTime=Sat Aug 27 14:14:17 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215365, encodeId=0bf512153657a, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201118/df82e0cde01a4cf691cd117ea1d92f92/e8f5384bf5a046e39e049573730dd6ec.jpg, createdBy=4b6d3851900, createdName=pqssy, createdTime=Thu Apr 28 17:01:52 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214781, encodeId=f2821214e819d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:06:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208204, encodeId=d32b1208204e7, content=每次都有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72e05569940, createdName=ms5000001906902679, createdTime=Sat Apr 02 18:25:07 CST 2022, time=2022-04-02, status=1, ipAttribution=)]
    2022-09-16 1480b77bm78暂无昵称

    深静脉血栓是无声杀手,重在预防

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1249424, encodeId=a7221249424be, content=深静脉血栓是无声杀手,重在预防, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21d85264172, createdName=1480b77bm78暂无昵称, createdTime=Fri Sep 16 22:59:20 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241367, encodeId=0ed4124136e1c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=827a8134685, createdName=ms7000001664629792, createdTime=Sat Aug 27 14:14:17 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215365, encodeId=0bf512153657a, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201118/df82e0cde01a4cf691cd117ea1d92f92/e8f5384bf5a046e39e049573730dd6ec.jpg, createdBy=4b6d3851900, createdName=pqssy, createdTime=Thu Apr 28 17:01:52 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214781, encodeId=f2821214e819d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:06:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208204, encodeId=d32b1208204e7, content=每次都有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72e05569940, createdName=ms5000001906902679, createdTime=Sat Apr 02 18:25:07 CST 2022, time=2022-04-02, status=1, ipAttribution=)]
    2022-08-27 ms7000001664629792

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1249424, encodeId=a7221249424be, content=深静脉血栓是无声杀手,重在预防, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21d85264172, createdName=1480b77bm78暂无昵称, createdTime=Fri Sep 16 22:59:20 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241367, encodeId=0ed4124136e1c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=827a8134685, createdName=ms7000001664629792, createdTime=Sat Aug 27 14:14:17 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215365, encodeId=0bf512153657a, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201118/df82e0cde01a4cf691cd117ea1d92f92/e8f5384bf5a046e39e049573730dd6ec.jpg, createdBy=4b6d3851900, createdName=pqssy, createdTime=Thu Apr 28 17:01:52 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214781, encodeId=f2821214e819d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:06:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208204, encodeId=d32b1208204e7, content=每次都有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72e05569940, createdName=ms5000001906902679, createdTime=Sat Apr 02 18:25:07 CST 2022, time=2022-04-02, status=1, ipAttribution=)]
    2022-04-28 pqssy

    ***

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1249424, encodeId=a7221249424be, content=深静脉血栓是无声杀手,重在预防, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21d85264172, createdName=1480b77bm78暂无昵称, createdTime=Fri Sep 16 22:59:20 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241367, encodeId=0ed4124136e1c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=827a8134685, createdName=ms7000001664629792, createdTime=Sat Aug 27 14:14:17 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215365, encodeId=0bf512153657a, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201118/df82e0cde01a4cf691cd117ea1d92f92/e8f5384bf5a046e39e049573730dd6ec.jpg, createdBy=4b6d3851900, createdName=pqssy, createdTime=Thu Apr 28 17:01:52 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214781, encodeId=f2821214e819d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:06:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208204, encodeId=d32b1208204e7, content=每次都有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72e05569940, createdName=ms5000001906902679, createdTime=Sat Apr 02 18:25:07 CST 2022, time=2022-04-02, status=1, ipAttribution=)]
    2022-04-26 su_yi_fei

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1249424, encodeId=a7221249424be, content=深静脉血栓是无声杀手,重在预防, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21d85264172, createdName=1480b77bm78暂无昵称, createdTime=Fri Sep 16 22:59:20 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241367, encodeId=0ed4124136e1c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=827a8134685, createdName=ms7000001664629792, createdTime=Sat Aug 27 14:14:17 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215365, encodeId=0bf512153657a, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201118/df82e0cde01a4cf691cd117ea1d92f92/e8f5384bf5a046e39e049573730dd6ec.jpg, createdBy=4b6d3851900, createdName=pqssy, createdTime=Thu Apr 28 17:01:52 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214781, encodeId=f2821214e819d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 20:06:28 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208204, encodeId=d32b1208204e7, content=每次都有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72e05569940, createdName=ms5000001906902679, createdTime=Sat Apr 02 18:25:07 CST 2022, time=2022-04-02, status=1, ipAttribution=)]
    2022-04-02 ms5000001906902679

    每次都有收获

    0